METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS Russian patent published in 2022 - IPC A61K39/00 A61P9/00 A61P13/12 A61P35/00 

Abstract RU 2771824 C2

FIELD: medicine.

SUBSTANCE: invention relates to the use of an inhibitor of dipeptidyl peptidase-3 (hereinafter – DPP3) activity for the treatment of a disease or condition accompanied or related to necrotic processes in an individual. The inhibitor of DPP3 activity is an anti-DPP3 antibody, a fragment of an anti-DPP3 antibody or scaffold protein, other than Ig, against DPP3, which bind to SEQ ID NO:1 or SEQ ID NO:2. The disease is selected from a group including heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, microbial infection, AIDS, malaria, SIRS, sepsis, cancer, acute kidney failure (AKI), seizures, neurodegenerative diseases, autoimmune diseases, vascular diseases and hypotension.

EFFECT: invention provides for the treatment of a disease or condition in an individual accompanied or related to necrotic processes, using an inhibitor of DDP3 activity.

5 cl, 12 tbl, 11 dwg, 14 ex

Similar patents RU2771824C2

Title Year Author Number
THERAPEUTIC GUIDANCE AND/OR MONITORING THERAPY FOR TREATING SHOCK 2020
  • Bergmann, Andreas
RU2835616C1
DPP3-BINDING MOLECULE AIMED AT SPECIFIC DPP3 EPITOPES AND BINDING TO THEM AND ITS USE FOR PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS, WHICH ARE RELATED TO OXIDATIVE STRESS 2018
  • Bergmann, Andreas
RU2787033C2
DPP3 FOR IMPLEMENTATION, MONITORING AND STRATIFICATION OF THERAPY WITH NT-ADM ANTIBODIES IN PATIENTS WITH SHOCK 2021
  • Bergmann Andreas
RU2838370C1
METHODS AND MATERIALS FOR ASSESSMENT OF RESPONSE TO THERAPY AGAINST PLASMA-BLASTS AND PLASMA CELLS 2017
  • Smithson, Glennda
  • Estevam, Jose
  • Jones, Nicholas
RU2787629C2
NGF ANTIBODIES AND RELATED METHODS 2019
  • Steiniger Sebastian C. J.
  • Dunkle William
  • Rugg Catherine
  • Dunham Steven A.
RU2838175C2
HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF 2016
  • Zhorzh Gi
  • Messner Ekkekhard
  • Lariver Loran
  • Khaas Aleksandr
  • Kettenberger Gubert
  • Ferrara Koller Klaudia
  • Shlotauer Tilman
  • Molkhoj Mikhel
RU2731156C1
FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS 2018
  • Cebe, Regis
  • Yowe, David Langdon
  • Olland, Stephane
RU2774368C2
COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER 2018
  • Shanto, Stefani
  • Gurden, Nikolya
  • Paturel, Karin
  • Perro, Ivan
  • Rossi, Benzhamin
RU2781116C1
ANTIBODIES SPECIFIC TO MMP9 2015
  • Chvatchko Missotten Ioland
  • Goffen Lorans
  • Lezher Olive
  • Dann Stiven M.
  • Pauer Kristin
  • Mondrel Kinsi
RU2714043C2
ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT 2017
  • Voors, Adriaan
RU2762059C2

RU 2 771 824 C2

Authors

Bergmann Dr. Andreas

Dates

2022-05-12Published

2017-04-20Filed